



Changes with Nutritional Products

➤ **SMA Althéra® and SMA Alfamino® formula for Cow's Milk Protein Allergy (CMPA)**

From 1 July 2026, Nestlé Health Science will introduce updated formulations of SMA SMA Althéra® and Alfamino® which will be known as SMA Althéra® Advance and SMA Alfamino® Advance.

The new formulations will include the addition of human milk oligosaccharides (HMO), thus aligning with international markets to enable consistent stock and there will be no difference in the cost.

Over the next months there will be a phased transition approach; therefore:

- Existing patients can remain on current formulations while stock lasts
 - SMA Althéra (EHF)
 - SMA Alfamino (AA)
- New patients should be commenced on the Advance formulations from 1 July 2026
 - SMA Althéra Advance (EHF)
 - SMA Alfamino Advance (AA)

The Advance formulations will be assigned new PIP codes; therefore, will require separate prescriptions. If an existing patient cannot obtain the old formulation, the prescription will need to be altered, with the same volume and quantity. Both products are on the Paediatric Formulary.

➤ **Vitajoule® - carbohydrate replacement**

Vitaflo has discontinued Vitajoule as of May 2026, which is a carbohydrate replacement used predominantly for metabolic patients. Although it is not a product that is used widely, the patients who require it have very complex requirements; therefore, it is essential to have on the formulary. Polycal (Nutrica) has been approved as a replacement on the Paediatric and Adult Nutritional Formulary.